ACM
AVDL

Arlington Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Arlington Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-115,902
Closed -$920K – 18
2020
Q1 		$920K Buy
+115,902
New +$890K 0.85% 14

Other funds holding AVDL

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Arlington Capital Management's AVDL Position: Q2 2020 in Review

Arlington Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q2 2020, closing a stake of 115,902 shares — an estimated $920K sold.

Arlington Capital Management first reported a position in AVDL in Q1 2020 and held it in 1 quarter. The position peaked at $920K in Q1 2020. 74 funds tracked by Wall St. Rank hold AVDL as of Q2 2020.

  • Arlington Capital Management reported no remaining Avadel Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Arlington Capital Management sold 115,902 Avadel Pharmaceuticals shares in Q2 2020, an estimated $920K.
  • Arlington Capital Management first reported a position in Avadel Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Arlington Capital Management's Avadel Pharmaceuticals position peaked at $920K in Q1 2020.
  • 74 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2020.

Based on Arlington Capital Management's 13F filing for Q2 2020, filed 10 Aug 2020.